

#3 1-16-91

07-24 (688) A



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE APPLICATION OF)

THOMAS F. DEUEL,)
YUE-SHENG LI,)
NED R. SIEGEL AND)
PETER G. MILNER)

GROUP ART UNIT: 186 ✓

SERIAL NUMBER: 07/542,232)

EXAMINER:)

FILED: JUNE 21, 1990)

TITLE: HEPARIN-BINDING GROWTH FACTOR)

SUPPLEMENTAL

INFORMATION DISCLOSURE STATEMENT

UNDER 37 CFR 1.97-1.99

Hon. Commissioner of Patents and Trademarks
Washington, D. C. 20231


90 DEC 20 11 17 15
GROUP 105

Dear Sir:

This is a supplement to the Information Disclosure Statement filed July 23, 1990 in the above-identified application. On December 11, 1990, the undersigned received a copy of European Patent Application 326,075, published August 2, 1989, but which he was not aware of previously. A copy of said application (identified herewith as document E), together with Form 1449, is enclosed for the convenience of the Examiner.

The relevance of document E is that it discloses a heparin-binding brain mitogen (HBBM) in which the disclosed 19 amino acids of the N-terminus are the same as the first 19 amino acids of the heparin-binding growth factor (HBGF-8) claimed herein. However, applicant's growth factor (HBGF-8) is derived from bovine uterus or human placenta whereas the protein (HBBM) described in document E is derived from brain tissues. Moreover, applicant's HBGF-8 is characterized by a complete amino acid sequence of 168 residues which is not disclosed in document E. In view of its brain tissue origin, the protein of document E appears to be the same as the heparin-binding protein of document D rather than applicant's novel HBGF-8.

Respectfully submitted,



Scott J. Meyer
Attorney for Applicants
Registration No. 25,275

Monsanto Company
800 N. Lindbergh Blvd.
Mail Zone - A3SD
St. Louis, Missouri 63167
(314) 694-3117

December 11, 1990